Earnings Call Summary | Revvity(RVTY.US) Q1 2024 Earnings Conference
Earnings Call Summary | Revvity(RVTY.US) Q1 2024 Earnings Conference
The following is a summary of the Revvity, Inc. (RVTY) Q1 2024 Earnings Call Transcript:
以下是Revvity, Inc.（RVTY）2024年第一季度業績電話會議記錄摘要：
Financial Performance:
財務業績：
Revvity reported Q1 revenues of $650 million, a decrease of 3% in organic revenue.
The company's Q1 adjusted operating margins rose to 25.5%, above expectations.
Free cash flow amounted to $132 million, with the anticipation of continued positive trends and added cash flows from last year's divestitures.
Adjusted EPS for Q1 was at $0.98, above the median of their expectations.
Revvity報告稱，第一季度收入爲6.5億美元，有機收入下降了3％。
該公司第一季度調整後的營業利潤率升至25.5％，高於預期。
自由現金流達1.32億美元，預計去年的資產剝離將帶來持續的積極趨勢並增加現金流。
第一季度調整後的每股收益爲0.98美元，高於預期的中位數。
Business Progress:
業務進展：
The company saw low-double-digit growth in its largest diagnostics segment, the immunodiagnostics franchise.
New product launches have begun in Revvity's Signals Software business, contributing to high single-digit growth in Q1.
The company successfully integrated several acquisitions, which it believes will bolster internal collaboration and enhance key initiatives.
Plans to streamline the company are in motion, focusing on footprint consolidation, logistical optimization, vendor consolidation, and in-sourcing opportunities.
The software business outperformed expectations with new product launches, anticipating high-single-digit to low-double-digit annual growth.
Revvity expects low-single-digit growth in its core reagents business for Q2, with mid-single-digit growth foreseen for the full year.
Strong growth in the newborn business and immunodiagnostics, outside of China, is expected to continue.
The company is taking steps to support pharma/biotech customers as they realign their portfolios, moving efficiently from discovery to development.
A new automated tuberculosis testing system was presented, significantly reducing hands-on time and technician touch points, providing a considerable competitive edge.
該公司最大的診斷領域——免疫診斷專營權——實現了低兩位數的增長。
Revvity的信號軟件業務已開始推出新產品，爲第一季度的高個位數增長做出了貢獻。
該公司成功整合了幾項收購，它認爲這將加強內部合作並加強關鍵舉措。
精簡公司的計劃正在進行中，重點是足跡整合、物流優化、供應商整合和內包機會。
軟件業務在新產品的發佈中表現超出預期，預計年增長將高個位數至低兩位數。
Revvity預計，其核心試劑業務將在第二季度實現低個位數的增長，預計全年將實現中等個位數的增長。
預計中國以外的新生兒業務和免疫診斷業務將繼續強勁增長。
該公司正在採取措施支持製藥/生物技術客戶調整其產品組合，高效地從發現轉向開發。
提出了一種新的自動化結核病檢測系統，顯著減少了動手時間和技術人員的接觸點，提供了相當大的競爭優勢。
More details: Revvity IR
更多詳情： 活力紅外
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。
譯文內容由第三人軟體翻譯。